Digital health's point-solution era is giving way to broader platforms, and the cost-savings claims those platforms make to employers often don't hold up to methodological scrutiny.
|Articles|March 4, 2015
The Emerging 505(b)(2) Marketplace Provides Opportunities for Generic Companies Seeking New Revenue Streams in the U.S.
The "cliff" has passed for pharma, but has just begun for generic companies that have benefited from the high number of drugs going off patent. CEOs of generic companies report they are considering a spectrum of solutions to bridge the revenue gap, but perhaps none are more valid than the U.S. FDA’s 505(b)(2) approval pathway, which can offer accelerated approval, reduced development costs, lower risk and, in certain cases, market exclusivity. In this article, readers will get an understanding of 505(b)(2), why developers are choosing it, how products are identified and models for development.
Related to this article
CORXEL’s Dr. Bo Liang on why efficacy is no longer obesity medicine's biggest gap — and the four unmet needs that define what comes next.
MRD Testing Is Becoming the Most Important Tool in Oncology Drug Development: Q&A with Eric Matthews
MRD testing is transforming oncology trials — compressing timelines, enriching populations, and generating earlier answers.
Novo Nordisk data show real-world weight loss after switching to its oral semaglutide pill, FDA's peptide rulemaking stalls while its enforcement arm targets compounded peptide sellers, and Avi Pardo flags a compliance blind spot in field teams' text messages with doctors.
Dr. Jeremy Levin joins Ken Banta to share why he believes biotech's future demands a new level of leadership and stakeholder education — and why "mission without method" is a wasted effort.
Real-world data from Novo's Octane study show patients who switched from injectable GLP-1 therapy to oral semaglutide lost an average of 4.1% of their body weight within three months.
Numerof's Michael Abrams on why directing employees to the most effective, economical clinicians is digital health's most valuable offering.
Life sciences spends billions on compliance — but WhatsApp, iMessage, and SMS conversations between field teams and HCPs remain invisible to oversight.
Trending on PharmExec
1
Novo Reports Real-World Data Showing Weight Loss After Switch to Oral Semaglutide Pill
2
Roundup: Hengrui Pharma and Novo Enter Exclusive License Agreement for HRS-1596, AstraZeneca Enters Collaboartion with Summit Therapeutics
3
New U.S. Guidance Lays Out Exemptions for 100% Tariffs: Report
4
As Peptide Rulemaking Stalls, FDA Enforcement Moves Forward
5